Pancreatic cancer, one of the most aggressive and lethal types of cancer, continues to present significant challenges in both ...

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

Novo Nordisk announced plans for a longer phase III trial testing its investigational obesity drug CagriSema, with regulatory ...

The fourth-quarter earnings season for the biotech sector is in full swing this week. A few bigwigs have already reported ...

AbbVie is a resurging Dividend King. Amgen's recent clinical setback makes its stock available at a discount. Gilead Sciences ...

Terns Pharmaceuticals' TERN-701 and TERN-601 face challenges in CML and obesity. Find out why TERN stock is not a strong buy amid tough competition.

Amgen posted strong earnings beat and has an attractive dividend, and technical chart forecasting positive future performance ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Elsewhere, cell therapy developer Turnstone Biologics announced a second round of layoffs and plans to explore “strategic alternatives.” ...